An additional noteworthy observation in this phase I trial was that, in this population of heavily pre-treated patients with multiple tumor types, the three responders to JTX-4014 had tumors that expressed PD-L1 in tumor types that are not typically PD-Li responsive. The gene discussed is CD274; the disease is neoplasm.